NPSP NPS Pharmaceutical Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NPSP NPS Pharmaceutical

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tuck	10/3/2013 12:42:58 PM
	Read Replies (1) of 363

From dav1234 of Ihub (thanks!), a thumbnail valuation from BofA: >>BofA initiates NPS Pharmaceuticals at Buy, sees big upside BofA starts NPS Pharmaceuticals (NPSP) at Buy.It looks like BofA is valuing Gattex (which is apparently seeing some off-label reimbursement of late) at around $23/share and Natpara (which may end up having higher peak sales than Gattex if you buy Leerink's thinking) at $20.Adding another $2 for royalties brings the price target to $45, representing a 35% premium to Wednesday's close.NPSP +1.4% premarket.<< I figure the market bounces when a shutdown deal is reached, and NPS could go to the high $30s. I think I am going to set a sell target of $37. If reached, I would watch for a rebuy on a pullback, but might just move on to other things I am watching. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next